Immediate Impact
1 from Science/Nature 53 standout
Citing Papers
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
2022 Standout
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
2021 Standout
Works of Fabrizio Nelli being referenced
Gemcitabine and Cisplatin in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Impact of Comorbidities on Safety and Efficacy Outcome
2005
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Fabrizio Nelli | 319 | 351 | 38 | 93 | 56 | 568 | |
| Sérigne Maguèye Gueye | 105 | 244 | 33 | 140 | 62 | 510 | |
| Yarkın Kamil Yakupoğlu | 134 | 237 | 121 | 151 | 43 | 596 | |
| Hyun Soo Ahn | 111 | 179 | 49 | 173 | 53 | 576 | |
| Agnese Fabbri | 407 | 240 | 32 | 86 | 62 | 610 | |
| Tomokazu Kimura | 95 | 201 | 59 | 203 | 59 | 513 | |
| Rafael Núñez-Nateras | 149 | 292 | 58 | 138 | 25 | 566 | |
| Varun Mittal | 171 | 174 | 46 | 106 | 46 | 625 | |
| Ruey-Kuen Hsieh | 289 | 265 | 50 | 102 | 43 | 646 | |
| Samuel Haywood | 167 | 286 | 21 | 88 | 48 | 520 | |
| G. Schott | 153 | 229 | 32 | 189 | 33 | 550 |
All Works
Login with ORCID to disown or claim papers
Loading papers...